Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”


Overview

Archive, CME credit no longer available
Release Date: May 23, 2008
Expiration Date: May 23, 2009

This activity consists of audio and visual recording of 7 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.

To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.

Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.


Needs and Objectives

Upon completion of this activity, learners will be able to:

• List the recent developments in HIV vaccine research efforts
• Design antiretroviral strategies that consider data on:
  
  • The appropriate initiation of antiretroviral therapy
  • The management of complicated failure and the role of resistance testing
  • Renal complications of HIV and its therapies
• Discuss the latest treatment issues in opportunistic infections and opportunistic infections and immune recontitution inflammatory syndrome
• Formulate appropriate strategies for managing mental health issues in HIV-infected patients
• Describe the incidence, diagnosis, management of non-HIV associated malignancies in HIV-infected patients
  

CME Credit

The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The International AIDS Society–USA designates this educational activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.


Intended Audience

This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
• Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years

This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.


Course Faculty

Chairs

John P. Phair, MD
Professor of Medicine, Emeritus
Feinberg Medical School of Medicine
Northwestern University
Chicago, Illinois

Harold A. Kessler, MD
Professor of Medicine and Immunology/Microbiology
Rush Medical College
Associate Director, Section of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Michael S. Saag, MD
Volunteer Member
International AIDS Society–USA
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Division of Infectious Diseases and
     The William C. Gorgas Center for Geographic Medicine
Director, Center for AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama

Speakers

Robert C. Bailey, PhD, MPH
Professor
Division of Epidemiology and Biostatistics
University of Illinois at Chicago
Chicago, Illinois

Eric S. Daar, MD
Professor of Medicine
David Geffen School of Medicine
University of California Los Angeles
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Los Angeles, California

Michael P. Dubé, MD
Professor of Clinical Medicine
Rand-Schrader Clinic
Los Angeles County and University of Southern California
    Medical Center
Los Angeles, California

Charles W. Flexner, MD
Professor of Medicine, Pharmacology, and International Health
Johns Hopkins University School of Medicine
Baltimore, Maryland

Ronald T. Mitsuyasu, MD
Professor of Medicine
David Geffen School of Medicine at UCLA
Director
UCLA Center for Clinical AIDS
Research and Education
University of California Los Angeles
Los Angeles, California

Kimberly Y. Smith, MD, MPH
Associate Professor of Medicine
Rush University Medical Center
Chicago, Illinois


Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.

IAS-USA Board of Directors

Constance A. Benson, MD
Dr Benson received research grants awarded to University of California, San Diego from Gilead Sciences. Dr Benson served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Merck, and Pfizer, and chaired Data and Safety Monitoring Boards for Johnson & Johnson Research, Ltd. (Australia) and Achillion. (Updated 05/06/08)

Judith S. Currier, MD
Dr Currier (3/12/07-2/15/08) received research grants to UCLA from Tibotec, Merck, GlaxoSmithKline and Theratechnologies and served as a consultant or received honoraria from Bristol-Myers Squibb, Pfizer, Merck, and Tibotec. In addition she serves on a data safety monitoring board for Koronnis and Achillion Pharmaceuticals. (Updated 02/15/08)

Carlos del Rio, MD
Dr del Rio (3/12/07–2/15/08) received research grants to Emory University from Merck, GlaxoSmithKline, Pfizer, the CDC and the NIH. He served as a consultant or received honoraria from Merck, Trinity Biotech and BMS. (Updated 02/15/08)

Joel E. Gallant, MD, MPH
Dr Gallant received research grants awarded to Johns Hopkins University School of Medicine from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, RAPID Pharmaceuticals, Schering Plough, Tibotec, and Vertex. He is a member of Data Safety and Monitoring Boards for Abbott, Gilead, and Koronis. (Updated 02/15/08)

Roy M. Gulick, MD, MPH
Dr Gulick received research grants to Cornell University from Panacos, Pfizer, Schering, and Tibotec. He served as an ad-hoc scientific advisor or consultant to Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Schering, Trimeris, Virco, and Virostatics. He also serves as Chair of a DSMB for Koronis. (Updated 03/24/08)

Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 05/22/08)

Douglas D. Richman, MD
Dr Richman served as a consultant to Anadys, Biota, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, Idinex, Koronis, Merck, Monogram, Pfizer, Roche, and Tobira. (Updated 05/09/08)

Michael S. Saag, MD
Dr Saag received grants and research support from, and has been a scientific advisor to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tibotec, and Virco. (Updated 05/09/08)

Robert T. Schooley, MD
Dr Schooley served as a consultant to Achillion, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram, Pfizer, TaiMed, Tibotec, and Vertex. He had stock options for Achillion and Monogram. (Updated 05/09/08)

Paul A. Volberding, MD
Dr Volberding, during the period from 1/1/07 through 1/1/08, served on scientific advisory boards for Bristol-Myers Squibb, Gilead, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering for an ongoing clinical trial. He received an unrestricted educational grant from GlaxoSmithKline-Italy. (Updated 03/05/08)

Course Faculty and Staff

Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.

Dr Bailey had no relevant financial affiliations to disclose. (Updated 05/09/08)

Dr Daar received honoraria from, served as a consultant to or was on the speakers’ bureaus of Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram, Pfizer, Roche, and Tibotec. (Updated 05/09/08)

Dr Dubé received research support, served as a consultant or received honoraria from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Tibotec and Theratec. (Updated 05/09/08)

Dr Flexner received research support or honoraria from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Tibotec, and Vertex. He served as a consultant to Boehringer Ingelheim, Inhibitex, Schering-Plough, and Sequoia Pharmaceuticals. (Updated 05/09/08)

Dr Kessler received grants or research support from Gilead, Merck, TheraTechnologies, and Tibotec. He served a consultant to or was on the speakers’ bureaus of Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, Tibotec, and Virco. He had stock options for Abbott, Merck, and GlaxoSmithKline. (Updated 05/09/08)

Dr Mitsuyasu received a research grant awarded to University of California Los Angeles from Pfizer. (Updated 05/09/08)

Dr Phair served as a consultant to Pfizer. (Updated 05/09/08)

Dr Saag received grants and research support from, and has been a scientific advisor to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tibotec, and Virco. (Updated 05/09/08)

Dr Smith served on scientific advisory boards and or speakers’ bureaus of Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer and Tibotec. (Updated 05/09/08)


IAS–USA CME Staff

Ms Jacobsen has no relevant financial affiliations to disclose.

Ms Wilson has no relevant financial affiliations to disclose.


Grant Support

This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.

Funding for the live activity, upon which this activity was based came from the following commercial companies:

Substantial Grants from:
Bristol-Myers Squibb
Tibotec Therapeutics
Abbott Laboratories
Gilead Sciences
Merck & Co., Inc.
Pfizer Global Pharmaceuticals

Generous Grants from:
GlaxoSmithKline

Additional grant support for this course:
Roche Laboratories


Discussion of Investigational or Unapproved Usage

This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.


Contact Information

If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:

International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2010@iasusa.org

I have read these instructions and understand them.